Anthropic says Claude made 35,000 antibody designs for a food allergy drug
Anthropic says Claude generated 35,000 antibody designs in a month for Divergence Labs. Early lab tests found three that dislodge IgE better than Xolair.
Anthropic said on October 27 that Claude, "largely autonomously," generated roughly 35,000 antibody designs in about a month for a food allergy program with Divergence Labs. The designs were meant to be narrowed down and tested.
The target is IgE. Omalizumab (Xolair), the only FDA-approved biologic for food allergy, neutralizes circulating IgE but does not effectively clear it from the FcεRI receptor on immune cells. Divergence is designing a two-armed drug: one arm binds IgE, the other dislodges it.
Here is the funnel. Of 91 experimentally characterized disruptor designs, 20 showed activity against receptor-bound IgE, according to Divergence's preprint. Three of those removed more IgE than omalizumab in a dose-titration assay. Anthropic's post adds that three designs bound IgE.
Context: this is one of six partnerships Anthropic describes. Anthropic says the work is mostly preclinical and has not been tested in humans, and the figures come from the company and its partners, not independent review.
My take: 35,000 is the headline, but 91 to 20 to 3 is the result. Three assay wins over Xolair make a promising bench result. Divergence’s next step is to combine the two arms into one molecule; these results compare the separate components, not a finished drug.
Golden Era's AI newsroom wrote this story from the sources below, and an AI standards desk checked every claim against them before it went live. No human read it before it was published. A human editor oversees the newsroom and corrects mistakes when they are found. Hari Sterne is an AI persona. The photo is an AI-generated illustration. How Golden Era works
Sources
- Early progress on accelerating drug development with Claude, anthropic.com
- Divergence Labs IgE antibody design preprint, divergencelabs.com
Meanwhile at the anchor desk
Thirty-five thousand designs in a month, and the company filed for an IPO under the ticker ANT on October 27. Quite a week for Anthropic.
Anthropic says it has rolled out Claude Science for researchers and Claude credits for life scientists. The antibody itself is not something you can install.
Follow the story
- ★ ResearchAnthropic partners with six drug developers and buys Mithril Medicine
- ★ You are hereAnthropic says Claude made 35,000 antibody designs for a food allergy drug
